公司概述
Check-Cap Ltd. operates as a clinical stage medical diagnostics enterprise specializing in capsule-based screening technology products, aiming to advance diagnostic capabilities within the healthcare sector. The company is positioned within the broader Healthcare sector and specifically functions in the Diagnostics & Research industry, where it seeks to develop and commercialize innovative screening solutions. As of the latest available data, the enterprise carries a market capitalization of $12.03M, though specific annual revenue and employee count figures are not disclosed in the provided financial records. These valuation metrics, particularly the relatively small market cap combined with the absence of reported revenue, indicate that the company remains in an early-stage development phase typical of clinical stage biotechnology firms, where capital is predominantly allocated toward research and product development rather than established commercial sales.
财务健康
The company reports a Net Income (TTM) of $-13,624,000, while its EBITDA stands at $-3,756,500, highlighting a significant divergence between bottom-line losses and operational cash generation before interest and taxes. This substantial gap between revenue (which is not reported) and net income reveals a cost structure where operating expenses and research expenditures likely far exceed current earnings potential, a common characteristic of pre-revenue diagnostic companies. Free Cash Flow for the trailing twelve months is reported at $-1,058,125, indicating that the company is currently consuming cash reserves to fund its operations and R&D initiatives rather than generating surplus liquidity. The balance sheet shows a cash position of $1.42M against total debt of $139,000, resulting in a Debt to Equity ratio of 3.69, which suggests the company is heavily leveraged relative to its equity base, although the absolute debt amount remains modest. The Current Ratio is recorded at 0.71, a figure below the standard benchmark of 1.0, indicating that the company's current liabilities exceed its current assets and pointing to potential short-term liquidity pressures. Furthermore, the Return on Equity is -130.1% and the Return on Assets is -20.8%, metrics that explicitly reveal that management has not yet generated positive returns on shareholder capital or asset base, reflecting the high-risk nature of the clinical stage business model.
估值评估
Trailing P/E and Forward P/E ratios are both listed as N/A due to the company's lack of positive net income, meaning traditional earnings-based valuation multiples cannot be calculated to assess expected earnings trajectory. The Price to Book ratio is 2.57, a metric indicating that the market is valuing the company at a significant premium relative to its tangible book value, which often occurs in biotech firms where intangible assets like intellectual property drive value rather than physical book value. While Price to Sales and EV/EBITDA are provided as N/A and -2.23 respectively, the negative EV/EBITDA of -2.23 further underscores that the company is currently unprofitable, making standard valuation comparisons with profitable peers difficult without context of future clinical milestones. The stock's 52-week trading range spans from a low of $0.59 to a high of $3.92, providing a historical volatility context for the share price. The Beta value is 0.79, which implies that the stock price tends to be less volatile than the broader market, moving with 21% less intensity than the market index on average. These valuation metrics collectively suggest that investors are pricing in significant future growth potential to offset the current lack of profitability and the high negative EV/EBITDA.
Growth & Income
Revenue Growth and Earnings Growth for the year-over-year period are both listed as N/A, as the company has not yet achieved consistent commercial revenue streams to calculate growth rates. In the absence of dividend payments, the Dividend Yield is N/A and the Payout Ratio is 0.0%, confirming that the company does not distribute cash to shareholders. Consequently, the company's financial strategy involves reinvesting all available earnings, or in this case, raising capital to fund growth, rather than paying dividends to investors. The overall growth and income profile of Check-Cap Ltd. is characterized by a complete reliance on external capital formation to sustain operations and advance its capsule-based screening technology, as it currently offers no income yield and has not demonstrated historical revenue expansion metrics.